Friday, February 25, 2022 7:14:32 PM
I overstated by saying "shut off" the Big Pharma Covid revenue stream. But if a vaccinated patient gets lenz after becoming reinfected following his 1st dose of a vaccine, lenz could eliminate a 2nd, 3rd, or 4th vaccination. So a significant portion of the Big Pharma revenue could be eliminated. That's enough incentive to pose a competitive challenge to the vaccine market.
I'd like to see lenz compounded in order to infuse enough of an infection to activate lenz, and then take ALL of the Covid vaccine market (which, in reality, would create an actual vaccine market, which we don't really have yet). But I already said that I have no idea if that is feasible. I just think that it may be. And I definitely think lenz could be administered in an outpatient setting, to those with a Covid diagnosis and elevated CRP levels.
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM